Лечение фибрилляции предсердий (обзор литературы)

Автор: Баталов Р.Е., Попов С.В., Егай Ю.В.

Журнал: Сибирский журнал клинической и экспериментальной медицины @cardiotomsk

Статья в выпуске: 4-1 т.26, 2011 года.

Бесплатный доступ

Представлены принципы лечения фибрилляции предсердий. Приводятся современные способы медикаментозного и немедикаментозного восстановления синусового ритма, профилактики тромботических осложнений, определяются тактика и возможности интервенционного лечения фибрилляции предсердий.

Фибрилляция предсердий, восстановление синусового ритма, поддержание синусового ритма, радиочастотная аблация фибрилляции предсердий

Короткий адрес: https://sciup.org/14919614

IDR: 14919614

Список литературы Лечение фибрилляции предсердий (обзор литературы)

Дедкова А.А., Суслова Т.Е., Кологривова И.В. и др. Провоспалительные цитокины и аутоантитела к кардиомиоцитам у пациентов с пароксизмальными наджелудочковыми тахикардиями//Сибирский медицинский журнал (Томск). -2010. -Т. 25, № 3, вып. 1. -С. 16-20.
Bellandi F., Simonetti I., Leoncini M. et al. Longterm efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation//Am. J. Cardiol. -2001. -Vol. 88, No. 6. -P. 640-645.
Bianconi L., Mennuni M. Comparison between propafenone and digoxin administered intravenously to patients with acute atrial fibrillation. PAFIT-3 Investigators. The Propafenone in Atrial Fibrillation Italian Trial//Am. J. Cardiol. -1998. -Vol. 82, No. 5. -P. 584-588.
Chevalier P., Durand-Dubief A., Burri H. et al. Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis.//J. Am. Coll. Cardiol. -2003. -Vol. 41, No. 2. -P. 255-262.
Chimienti M., Cullen M.T., Casadei G. Safety of longterm flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators//Am. J. Cardiol. -1996. -Vol. 77, No. 3. -P. 60A-75A.
Crijns H.J., van Wijk L.M., van Gilst W.H. et al. Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens//Eur. Heart. J. -1988. -Vol. 9, No. 6. -P. 634-638.
De Paola A.A., Veloso H.H. Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation. SOCESP Investigators. The Cardiology Society of Sao Paulo//Am. J. Cardiol. -1999. -Vol. 84, No. 9. -P. 1033-1037.
Deedwania P.C., Singh B.N., Ellenbogen K. et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators//Circulation. -1998. -Vol. 98, No. 23. -P. 2574-2579.
Fetsch T., Bauer P., Engberding R. et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Prevention of Atrial Fibrillation after Cardioversion Investigators//Eur. Heart. J. -2004. -Vol. 25, No. 16. -P. 1385-1394.
Fuster V., Ryden L.E., Cannom D.S. et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation)//Eur. Heart. J. -2006. -Vol. 27. -P. 1979-2030.
Haissaguerre M., Jais P., Shah D.C. et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins//N. Engl. J. Med. -1998. -Vol. 339. -P. 659-666.
Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. AFFIRM First Antiarrhythmic Drug Substudy Investigators//J. Am. Coll. Cardiol. -2003. -Vol. 42, No. 1. -P. 20-29.
McMurray J., Kober L., Robertson M. et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial//J. Am. Coll. Cardiol. -2005. -Vol. 45, No. 4. -P. 525-530.
Meinertz T., Lip G.Y., Lombardi F. et al. Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study)//Ibid. Там же. Ibid. Там же. Am. J. Cardiol. -2002. -Vol. 90, No. 12. -P. 1300-1306.
Nademanee K., McKenzie J., Kosar E. et al. A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate//J. Am. Coll. Cardiol. -2004. -Vol. 43. -P. 2044-2053.
Pappone C., Santinelli V., Manguso F. et al. Pulmonary vein denervation enhances longterm benefit after circumferential ablation for paroxysmal atrial fibrillation//Circulation. -2004. -Vol. 109. -P. 327-334.
Pedersen O.D., Bagger H., Keller N. et al. Efficacy of dofetilide in the treatment of atrial fibrillationflutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy//Circulation. -2001. -Vol. 104, No. 3. -P. 292-296.
Pritchett E.L., Page R.L., Carlson M. et al. Efficacy and safety of sustained#release propafenone (propafenone SR) for patients with atrial fibrillation. Rythmol Atrial Fibrillation Trial (RAFT) Investigators//Am. J. Cardiol. -2003. -Vol. 92, No. 8. -P. 941-946.
Stroobandt R., Stiels B., Hoebrechts R. Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators//Am. J. Cardiol. -1997. -Vol. 79, No. 4. -P.418-423.
Roy D., Talajic M., Dorian P. et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators//N. Engl. J. Med. -2000. -Vol. 342, No. 13. -P. 913-920.
Singh S., Zoble R.G., Yellen L. et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study//Circulation. -2000. -Vol. 102, No. 19. -P. 2385-2390.
Slavik R.S., Tisdale J.E., Borzak S. Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence//Prog. Cardiovasc. Dis. -2001. -Vol. 44, No. 2. -P. 121-152.
Stambler B.S., Wood M.A., Ellenbogen K.A. et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators//Circulation. -1996. -Vol. 94, No. 7. -P. 1613-1621.
Van Gelder I.C., Hagens V.E., Bosker H.A. et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation//N. Engl. J. Med. -2002. -Vol. 347. -P. 1834-1840.
Vos M.A., Golitsyn S.R., Stangl K. et al. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group//Heart. -1998. -Vol. 79, No. 6. -P. 568-575.
Wyse D.G., Waldo A.L., DiMarco J.P. et al. A comparison of rate control and rhythm control in patients with atrial fibrillation//N. Engl. J. Med. -2002. -Vol. 347. -P. 1825-1833.
Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study//Stroke. -1991. -Vol. 22. -P. 983-988.
Ezekowitz M.D., James K.E., Nazarian S.M. et al. Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. The Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators//Circulation. -1995. -Vol. 92. -P. 2178-2182.
Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation//Ann. Intern. Med. -2007. -Vol. 146. -P. 857-867.
Waldo A.L., Becker R.C., Tapson V.F. et al. NABOR Steering Committee. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation//J. Am. Coll. Cardiol. -2005. -Vol. 46. -P. 1729-1736.
Gorin L., Fauchier L., Nonin E. et al. Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score 1//Thromb. Haemost. -2010. -Vol. 103. -P. 683-685.
Hohnloser S.H., Crijns H.J., van Eickels M. et al. Effect of dronedarone on cardiovascular events in atrial fibrillation//N. Engl. J. Med. -2009. -Vol. 360. -P. 668-678.

Еще

Статья научная